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Abstract
Introduction Cancer is a leading cause of death in Americans.
We have identified an inducible cancer avoidance mechanism in
cells that reduces mutation rate, reduces and delays
carcinogenesis after carcinogen exposure, and induces
apoptosis and/or senescence of already transformed cells by
simultaneously activating multiple overlapping and redundant
DNA damage response pathways.
Methods The human breast carcinoma cell line MCF-7, the
adriamycin-resistant MCF-7 (Adr/MCF-7) cell line, as well as
normal human mammary epithelial (NME) cells were treated with
DNA oligonucleotides homologous to the telomere 3' overhang
(T-oligos). SCID mice received intravenous injections of MCF-7
cells followed by intravenous administration of T-oligos.
Results Acting through ataxia telangiectasia mutated (ATM) and
its downstream effectors, T-oligos induced apoptosis and
senescence of MCF-7 cells but not NME cells, in which these
signaling pathways were induced to a far lesser extent. In MCF-
7 cells, experimental telomere loop disruption caused identical
responses, consistent with the hypothesis that T-oligos act by
mimicking telomere overhang exposure. In vivo, T-oligos greatly
prolonged survival of SCID mice following intravenous injection
of human breast carcinoma cells.
Conclusion By inducing DNA damage-like responses in MCF-7
cells, T-oligos provide insight into innate cancer avoidance
mechanisms and may offer a novel approach to treatment of
breast cancer and other malignancies.
Introduction
Breast cancer is the leading cancer among women [1]. Ther-
apy for advanced disease relies largely on chemotherapy and
radiation therapy (reviewed in [2-5]), both of which have signif-
icant host toxicity and themselves promote mutations, fueling
disease progression and treatment resistance.
Despite progress in treatment modalities for patients with met-
astatic disease, median survival is two to three years [6] and
treatment with single or multiple chemotherapeutic agents is
invariably toxic to normal proliferating tissues [6]. Promising
novel therapies directed at specific malfunctioning proteins,
including anti-receptor tyrosine kinase antibodies [7], will no
doubt greatly improve treatment outcomes. Still, to date,
despite substantial variability in patient survival, metastatic
breast cancer is almost invariably fatal (reviewed in [5,8]).
Recent work from our laboratory [9-15] suggests the exist-
ence of innate inducible cellular responses, initiated by expo-
sure of the telomere repeat sequence TTAGGG at the time of
telomere loop disruption and mediated through multiple redun-
dant signaling pathways, that act to retard cancer initiation and
progression by selectively eliminating cells with acute severe
DNA damage or after multiple rounds of cell division [16].
These responses fail to occur in malignant cells, despite their
loss of normal check points and often gross DNA
Ad = adenovirus; ATM = ataxia telangiectasia mutated; ATR = ATM-Rad3-related; BrdU = 5-bromo-2'-deoxyuridine; β-gal = β-galactosidase; FAM = 
fluorescein phosphoramidite; FBS = fetal bovine serum; GFP = green fluorescent protein; HBSS = Hank's buffered salt solution; MDR = multiple 
drug resistant; NME = normal mammary epithelial; PBS = phosphate-buffered saline; pRb = retinoblastoma protein; SA = senescence-associated; 
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abnormalities, but can be triggered by providing cells or tis-
sues with DNA oligonucleotides homologous to the telomere
3' overhang (T-oligos) [9,13,17]. A large number of partially
and completely homologous sequences have been found
effective [9-14,17,18], with longer sequences generally hav-
ing a higher molar efficacy than shorter ones, at least in the 2
to 20 base range [18,19].
Telomeres exist in a loop structure that is stabilized by telom-
eric repeat binding factor (TRF)2 [12]. Disruption of the loop
by a dominant negative construct (TRF2DN) leads to apoptosis
of certain mammalian cells [20] and senescence of others
[10,20], mediated at least in part through the ataxia tel-
angiectasia mutated (ATM) kinase, with subsequent p53 acti-
vation [10,20-22], demonstrating that telomere loop
disruption in some way constitutes a DNA damage signal. We
have shown that exposure of cells to T-oligos leads to dose-
dependent DNA damage responses in both normal and malig-
nant cells, mediated at least in part through the ATM kinase
and its effector proteins p53, p73, p95/Nbs1, and E2F1 [9-
11,13]. Moreover, in several human malignant cell types,
including lymphoma, melanoma, fibrosarcoma, and squamous
cell carcinoma, T-oligos induce differentiation, apoptosis and/
or senescence [9,13,17], and strikingly reduce tumor burden
in a mouse xenograft model of human melanoma [13]. These
cellular responses occur without affecting the cells' own tel-
omeres [9,15], and appear to be far more pronounced in
malignant cells than in their normal counterparts [13,20]. T-oli-
gos have also been shown to activate p53 and to enhance
DNA repair rate in intact murine skin and human skin explants
[12,23] and to decrease mutation rate and photocarcinogen-
esis after UV irradiation in mice [12]. Because the telomere
overhang, repeats of TTAGGG, is concealed within the proxi-
mal duplex telomere except at times of experimental opening
of the telomere loop, or presumptively following physiological
stimuli such as acute DNA damage or critical telomere short-
ening during serial cell passage or transiently at times of DNA
replication [9,10,15], and because T-oligos rapidly accumu-
late in the nucleus [9,19], we hypothesize that T-oligos mimic
exposure of the overhang and are interpreted by the cell as
indicating that these anti-cancer responses should be
initiated.
DNA damage characteristically leads to phosphorylation of
ATM on serine 1981 [24,25]. ATM then phosphorylates p53
on serine-15 [26,27], p95/Nbs1 on serine 343 [21] and his-
tone H2AX on serine 139 [28,29]. DNA damage also induces
E2F1, a process dependent on both the ATM and the ATM-
Rad3-related (ATR) kinases [30]. As well, E2F1 transcription-
ally upregulates p73 [31], a structural and functional homolog
of p53 that accumulates in response to DNA damage. In nor-
mal human fibroblasts, prolonged T-oligo treatment induces
irreversible growth arrest and p53 phosphorylation as well as
induction of p16, p53, p21, p95/Nbs-1 and senescence-asso-
ciated (SA) β galactosidase (β-gal) activity [10], mimicking
both serial passage to senescence (reviewed in [10,32]) and
telomere loop disruption by TRF2DN [10].
To further test our hypothesis regarding the T-oligo mecha-
nism of action [14,16] and to quantify T-oligo therapeutic
effects, we studied the breast carcinoma line MCF-7 and the
same line after being rendered resistant to adriamycin. We
also compared the T-oligo effect on MCF-7 cells to its effect
on normal mammary epithelial (NME) cells. In cancerous cells,
T-oligo induces apoptosis and senescence of MCF-7 (p16-
null) and adriamycin resistant MCF-7 (p16 null, non-functional
p53, multiple drug resistant (MDR)-1 positive) breast cancer
cells, but these effects are significantly less prominent in NME
cells. We also demonstrate that systemic administration of T-
oligos significantly prolongs the survival of severe combined
immunodeficient (SCID) mice in a model of metastatic breast
cancer.
Materials and methods
Materials
Two DNA oligonucleotides were designed, one homologous
to the telomere overhang (T-oligo, GTTAGGGTTAG) and one
complementary to this sequence (Control-oligo, CTAAC-
CCTAAC) (Midland Certified Reagent, Midland, TX, USA).
Oligonucleotides were resuspended in H2O and subsequently
diluted in culture medium for a final concentration of 40 μM. In
all experiments, T-oligo was added only once. Cisplatin
(Sigma, St Louis, MO, USA) was used at a final concentration
of 10 μM and ICI 182,780 (Tocris Cookson Inc., Ellisville, MI,
USA) at 100 nM. For in vivo experiments, GTTAGGGTTAG
and a 16-base T-oligo, GGTTAGGTGTAGGTTT, were
obtained from Trilink (San Diego, CA, USA). For immunofluo-
rescent studies, the 11mer GTTAGGGTTAG was tagged with
fluorescein phosphoramidite (FAM) on the 3' end (Midland).
For in vivo studies, the intravenous dose of the 16-mer was 60
versus 120 nmoles of the 11mer, doses calculated as equiva-
lent to 20 μM versus 40 μM when diluted in the mouse blood
volume (estimated at 1.5 ml) immediately after injection.
Cell culture
MCF-7 (estrogen receptor-α positive, p16 null, wild-type p53)
cells were a gift of Dr Brown (Division of Molecular and Cellu-
lar Oncology, Department of Medical Oncology, Dana-Farber
Cancer Institute Boston, MA, USA). Cells were maintained in
MEM supplemented with 200 mM L-glutamine and Earle's
BSS adjusted to contain 1.5 g/l sodium bicarbonate, 0.1 mM
non-essential amino acids and 1 mM sodium pyruvate and
supplemented with 0.01 mg/ml bovine insulin, and 10% FBS.
Adriamycin resistant MCF-7 cells (Adr/MCF-7) [33] were
maintained in the above medium supplemented with 1.5 μg/ml
doxorubicin (Sigma Co., St Louis, MO, USA). NME cells were
obtained from Clonetics (Walkersville, MD, USA) and main-
tained in Mammary Epithelial Cell Growth Medium supple-
mented with brain pituitary extract, human epidermal growthAvailable online http://breast-cancer-research.com/content/9/1/R13
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factor, hydrocortisone, insulin, gentamicin and amphotericin B
according to the manufacturer's instructions. FBS (5%) was
added at the time of definitive experiments.
Immunofluorescent microscopy
Cells were provided 40 μM of FAM-labeled oligonucleotides.
After 60 minutes, medium was removed and cells were fixed in
3.7% formaldehyde (10 minutes) followed by 0.1% Triton X-
100, 2 mM EDTA (pH 7.4), 0.5 mg/ml RNase A and 0.375 mM
propidium iodide in PBS (10 minutes). Intracellular T-oligo was
visualized using a multicolor fluorescent microscope (Nikon),
providing excitation at 488 nm and 583 nm and detection at
503 to 530 nm (green-FAM channel) and 560 nm (red-propid-
ium iodide channel) at constant settings for paired dishes in
each experiment. Digital images were obtained.
Western blot analysis and antibodies
Western blot analysis was performed as described [34]; 50 to
100 μg protein/lane were processed. Antibody reactions were
performed with mouse monoclonal or rabbit polyclonal anti-
bodies: anti-p53 (DO-1, Ab-6) and anti p73 (Ab-4) (Onco-
gene Research Products, Cambridge, MA, USA), anti-
phospho-p53 ((Ser-15), 9284), anti-phospho-Rb (Ser 795),
anti-phospho-p95/Nbs1 (Ser 343) and anti-phospho-H2AX
(Ser 139) (Cell Signaling Technology, Beverly, MA, USA), anti-
p21/SDI1 (C24420; Transduction Laboratories, Lexington,
KY, USA), anti-phospho-ATM (Ser 1981; Rockland, Gilberts-
ville, PA, USA) and anti-E2F-1 (Santa Cruz Biotechnology,
Santa Cruz, CA, USA). Antibody binding was detected by the
ECL detection kit (Amersham, Piscatawya, NJ, USA), followed
by autoradiography (Kodak X-Omatic AR).
Densitometric analysis
Autoradiograms were scanned into a computer (PC Dell™).
Band intensity was determined after background subtraction
using BIO-RAD Gel Doc 1000/2000 imaging densitometer
(BIO-RAD, Hercules, CA, USA).
Cell yield
After removing the medium and rinsing with PBS, cultures
were incubated in 0.25% trypsin at 37°C and cell yields were
determined using a particle counter (Coulter Corp., Miami, FL,
USA).
Cell cycle analysis
Cells from duplicate cultures were collected, fixed in ethanol,
stained with propidium iodide [10] and analyzed for DNA con-
tent using FACScan analysis (Becton Dickinson, San Jose,
CA, USA). The distribution of cells between different phases
of the cell cycle was determined using the CELLQUEST pro-
gram (Becton Dickinson, San Jose, CA).
Apoptosis
TUNEL analysis
Apoptosis was determined as described [35]. Cells were col-
lected, fixed in 4% paraformaldehyde, permeabilized with
0.1% Triton X-100 in 0.1% sodium citrate, then incubated with
fluorescein-tagged dUTP in the presence of terminal deoxynu-
cleotidyl transferase (Boehringer Mannheim Biochemicals,
Mannheim, Germany) and cellular fluorescence was analyzed
by flow cytometry (Becton Dickinson).
ELISA
DNA fragmentation as a measure of apoptosis was deter-
mined using the cell death detection ELISAPLUS kit and follow-
ing the manufacturer's instructions (Roche Diagnostics,
Indianapolis, IN, USA) [36]. Briefly, MCF-7 and NME cells
were stimulated with T-oligo GTTAGGGTTAG (40 μM) or
diluent and cells were harvested 96 hours after stimulation.
Cells (1 × 104) were used as the antigen source in a sandwich
ELISA assay with a primary anti-histone antibody coated to the
microtiter plate and a secondary anti-DNA antibody coupled to
peroxidase.
BrdU incorporation assay
MCF-7 and NME cells cultured on Permanox chamber slides
were treated with T-oligo (GTTAGGGTTAG, 40 μM) or diluent
alone for seven days and then were re-fed with medium lacking
oligonucleotides. DNA synthesis was assayed using the 5-
bromo-2'-deoxyuridine (BrdU) Labeling and Detection Kit II
(Roche Molecular Biochemicals, Indianapolis, IN, USA) follow-
ing the manufacturer's protocol. Briefly, cells were labeled for
1 hour with BrdU, fixed and incubated with anti-BrdU mono-
clonal antibody. After incubation with anti-mouse Ig-alkaline
phosphatase, the color reaction was detected and pictures of
several representative fields were obtained. Four different
fields were analyzed and percent positive cells was calculated.
For NME cells that grow in colonies, BrdU labeled cells were
determined throughout the colonies in subconfluent cultures.
TRF2DN transfection
The myc-tagged adenovirus (Ad)TRF2DN expression vector
was the gift of Dr de Lange (The Rockefeller University, New
York, NY, USA). We plated 3.6 × 103 cells/cm2. One day later,
cultures were supplemented with 7 × 1010 viral particles/ml of
either AdTRF2DN or Ad-green fluorescent protein (GFP; con-
trol). The next day, medium was changed and the transfection
was repeated. Cells were collected at different intervals.
SA β-galactosidase staining
Cells were treated once with diluent, T-oligo or control oligo
for one week, fixed for 3 to 5 minutes, and incubated at 37°C
(no CO2) overnight with fresh SA β-gal stain solution as
described [32].Breast Cancer Research    Vol 9 No 1    Yaar et al.
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Animal model
Studies were performed in accordance with Boston Univer-
sity's animal review board. Nine-week slow release 17-β-estra-
diol pellets (#SE121, Innovative Research of America,
Sarasota, FL, USA) were injected subcutaneously into six-
week-old SCID mice (Fox-Chase Cancer Center, Philadelphia,
PA, USA). One day later, 2 × 106 MCF-7 cells were injected
intravenously into the tail vein of each mouse. Then, 3 days
later, groups of 5 mice each began receiving blinded intrave-
nous injections: the 11-base T-oligo (120 nmoles/injection, 23
mg/kg, 100 μl solution in Hank's buffered salt solution (HBSS)
assuming a 1.5 ml blood volume distribution) twice daily 5
days/week for 1 week; the 16-base T-oligo (60 nmoles/injec-
tion, 15 mg/kg); or diluent alone (HBSS). The same regimen
was repeated on day 31, after the first mouse died. Animals
were inspected and weighed twice weekly and euthanized
when they lost ≥15% of their body weight within 7 days.
Statistical analysis
Differences in cell yields, in the level of cytoplasmic DNA-his-
tone complexes and in BrdU incorporation were determined
using General Linear Model with post hoc analysis (SPSS Inc.,
statistical package version 10.0, Chicago, IL, USA). Differ-
ences in S phase distribution were determined by one way
ANOVA with post hoc analysis. Differences in SCID mice sur-
vival were determined by the Kaplan-Meier survival test (SPSS
Inc.).
Results
T-oligo localizes to nuclei
To determine if oligonucleotides comparably enter MCF-7 and
NME cells, cultures were provided FAM-labeled GTTAGGGT-
TAG and, within 30 to 60 minutes, T-oligo localization was
examined using a multicolor fluorescent microscope. As previ-
ously observed in multiple normal and malignant cell types
[9,19], T-oligo rapidly localized to the nuclei comparably well
in both cell types (Figure 1) and the majority of nuclei were
positive. No green fluorescence was observed in control, dilu-
ent-treated cells (data not shown).
T-oligo inhibits cell growt
To determine the effect of T-oligo (11mer, 40 μM) on cell
growth, we examined MCF-7 and NME cell yields up to 96
hours after a single supplementation of T-oligo (Figure 2). A
decrease in MCF-7 yield was observed as early as 1 day after
treatment. Diluent and control-oligo treated cells displayed
exponential growth versus extremely little or no growth of T-
oligo-treated cells. T-oligo decreased MCF-7 yields by 87 ±
9% within 4 days when the experiment was terminated (Figure
2a). Similarly, T-oligo inhibited NME proliferation, although the
magnitude of the effect was smaller, with yields decreased by
only 65.5 ± 0.01% after 4 days (Figure 2b). Modest but statis-
tically less inhibition was observed in control oligo-treated
cells.
T-oligo induces S phase cell cycle arrest of MCF-7 cells
To determine if the T-oligo effect on MCF-7 yields is due, at
least in part, to an effect on the cell cycle, MCF-7 cells were
treated as above (Figure 2c). A single supplementation of T-
oligo produced S phase cell cycle arrest, as reported previ-
ously for other cell types [9,13,17,37] with 66 ± 1% and 51 ±
7% of cells arrested in S phase at 48 and 96 hours, respec-
tively. As before, control oligo had a far lesser effect.
T-oligo induces apoptosis of MCF-7 cells
To determine if the T-oligo effect on cell yields in MCF-7 and
NME cells is due to apoptosis in addition to S phase arrest,
cultures were stimulated with T-oligo as above and TUNEL
assays were performed and levels of cytoplasmic DNA-his-
tones were determined 96 hours after stimulation (Figure 3).
While in MCF-7 cells T-oligos induced substantial apoptosis,
as shown by the prominent shift in the fluorescent peak (Figure
3a), in NME cells there was less of a shift (Figure 3b). In
Figure 1
T-oligos localize to nuclei T-oligos localize to nuclei. MCF-7 and normal mammary epithelial 
(NME) cells were supplemented with fluorescein phosphoramidite 
(FAM) labeled GTTAGGGTTAG and uptake was determined 30 to 60 
minutes after supplementation. Multicolor fluorescent microscopy 
showed that FAM-labeled T-oligos accumulated in the nucleus as 
determined by colocalization of propidium iodide (PI) nuclear staining 
(red) with FAM (green), producing an orange color. As expected, no 
green fluorescence was observed in control, diluent-treated cells.Available online http://breast-cancer-research.com/content/9/1/R13
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addition, the level of cytoplasmic DNA-histone complexes was
significantly higher (p < 0.03) in T-oligo-treated MCF-7 cells
than in NME cells (Figure 3c), in which the level of cytoplasmic
DNA-histone complexes was identical to the background level
(p  = 0.9), showing that T-oligo induces significantly more
apoptosis in MCF-7- than in NME cells, thus accounting for
the greater reduction in cell yields.
T-oligo induces senescence of MCF-7 cells
To determine the fate of the remaining non-apoptotic cells, we
investigated whether T-oligo induces senescence. Cells were
treated once at time 0 with T-oligo or diluent alone and, after
Figure 2
T-oligo decreases cell yield and induces S phase arrest in MCF-7 cells T-oligo decreases cell yield and induces S phase arrest in MCF-7 cells. 
Preconfluent cultures of (a) MCF-7 cells and (b) normal mammary epi-
thelial (NME) cells were treated with 40 μM of GTTAGGGTTAG (T-
oligo), CTAACCCTAAC (control oligo) or diluent alone and cell yields 
were determined at different intervals after oligonucleotide addition. 
Compared to controls, within 4 days T-oligo decreased cell yields 87 ± 
9% (MCF-7; p < 0.04, n = 4) and 65.5 ± 0.01% (NME; p < 0.03, n = 
2). (c) MCF-7 cells were treated as above and cells were collected for 
up to 96 hours for FACScan analysis after a single treatment at time 0. 
Averages and standard deviations were determined from duplicate 
samples. T-oligo increased the percent of cells in the S phase of the 
cycle as early as 48 hours after stimulation (p < 0.001, n = 2) and for at 
least 96 hours after stimulation (p < 0.04, n = 2).
Figure 3
T-oligo induces apoptosis of MCF-7 cells T-oligo induces apoptosis of MCF-7 cells. MCF-7 and normal mammary 
epithelial (NME) cells were treated as above. Apoptosis was deter-
mined by TUNEL analysis and by the level of cytoplasmic DNA-histone 
complexes 96 hours after a single treatment at time 0. (a) MCF-7 cells 
underwent apoptosis as observed by the prominent shift in fluorescent 
peak. (b) In contrast, there was only a minimal shift in the fluorescent 
peak of NME cells. (c) There is a significant increase in the levels of 
cytoplasmic DNA-histone complexes in T-oligo-treated MCF-7 cells 
compared to diluent-treated MCF-7 cells (p < 0.02, n = 3). In contrast, 
DNA-histone complexes in NME cells were not significantly increased 
above the background (Bkgd) level (p = 0.89).Breast Cancer Research    Vol 9 No 1    Yaar et al.
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seven days, were fixed and stained for SA β-gal activity, a
marker for senescence in at least some cell types [32]. Paired
cultures were supplemented after seven days with fresh
medium lacking oligonucleotides or diluent. BrdU incorpora-
tion and retinoblastoma protein phosphorylation (MCF-7 only)
were determined after an additional 24 hours. In MCF-7 cells,
T-oligo induced senescence of 61.3 ± 7.7% cells, compared
to diluent and control oligo, which induced senescence in 6.3
± 3.8% and 12 ± 2% of the cells, respectively, as determined
by SA β-gal activity (p < 0.015; Figure 4a).
Similarly, after provision of medium without T-oligo, BrdU
incorporation in MCF-7 cells significantly differed between the
cultures previously treated with T-oligo (7.4 ± 3.3%) and those
previously treated with diluent (30.4 ± 9.8%) or control oligo
(23 ± 6.4%) (p < 0.05), consistent with T-oligo induced
senescence (Figure 4b). There was no statistically significant
difference between diluent and control oligo pre-treated cul-
tures (p = 0.5). Conversely, in NME cells, BrdU incorporation
between cultures previously treated with T-oligo versus diluent
alone and control oligo did not differ, displaying 7.1 ± 2.2%,
6.3 ± 1.1% and 7.8 ± 1.2% BrdU-positive cells, respectively
(p = 0.5), suggesting that NME cells do not undergo senes-
cence, at least not within 7 days after T-oligo treatment (Figure
4c).
Finally, it is well established that, in senescent cells, retinoblas-
toma protein (pRb) remains in a hypophosphorylated state
despite growth stimulation [38]. To further examine the
senescene-like effect of T-oligo, we determined pRb phospho-
rylation in T-oligo treated MCF-7 cells versus controls. T-oligo
treated MCF-7 cells failed to phosphorylate pRb despite fresh
medium supplementation, while diluent or control-oligo treated
cultures displayed strong pRb phosphorylation (Figure 4,
inset). These studies demonstrate that T-oligo induces senes-
cence in the remaining MCF-7 cells, those that have not under-
gone apoptosis, but not in NME cells.
T-oligo and TRF2DN activate cell cycle and apoptosis 
regulatory proteins
MCF-7 and NME cells were treated as above and total cellular
proteins were harvested at different intervals after stimulation.
As determined by protein phsophorylation, T-oligo activated
the ATM kinase, known to be activated by DNA damage or crit-
ically short telomeres [39-41]. Similarly, T-oligo activated
(phosphorylated) the downstream effector proteins p53
Figure 4
T-oligo induces senescence of MCF-7 cells T-oligo induces senescence of MCF-7 cells. (a,b) MCF-7 and (c) normal mammary epithelial (NME) cells were treated with T-oligo once for seven 
days and then were either fixed and stained for senescence-associated (SA) β-galactosidase (β-gal) activity (a), or were supplemented with fresh 
medium lacking oligonucleotides and 5-bromo-2'-deoxyuridine (BrdU) incorporation (b,c) and retinoblastoma protein phosphorylation (inset) were 
determined. (a) In MCF-7 cells, T-oligo induced senescence of 61.3 ± 7.7% cells, compared to diluent and control oligo in which 6.3 ± 3.8% and 12 
± 2% of the cells, respectively, were senescent, as determined by SA β-gal activity (p < 0.015). (b) In MCF-7 cells, after T-oligo removal and provi-
sion of medium without T-oligo, only 7.4 ± 3.3% of cells displayed BrdU incorporation compared to 30.4 ± 9.8% and 23 ± 6.4% of diluent and con-
trol oligo pretreated cells, respectively (p < 0.05). (c) In NME cells, BrdU incorporation did not differ between T-oligo and diluent-treated cultures 
(7.1 ± 2.2% versus 6.3 ± 1.1% and 7.8 ± 1.2%, respectively; p = 0.5). Inset: MCF-7 cells were treated as above. Despite supplementation of fresh 
medium lacking T-oligo, no phosphorylation of retinoblastoma protein (pRb) was detected in T-oligo pretreated cultures. C, control-oligo; D, diluent; 
T, T-oligo.Available online http://breast-cancer-research.com/content/9/1/R13
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(serine 15), p95/Nbs1 (serine 343) and H2AX (serine 139)
(Figure 5a). T-oligo also induced the levels of E2F1, albeit
more rapidly and transiently, and induced the level of the p53-
dependent downstream apoptosis effector protein BAX [42]
and p21 [43] (Figure 5a).
In contrast, although T-oligo phosphorylated p53 and H2AX in
NME cells, the magnitude of these inductions was smaller in
NME cells (≤3-fold and ≤6-fold, respectively, at 24 to 72
hours) compared to MCF-7 cells (up to >12-fold and >21-
fold, respectively, through at least 96 hours) (Figure 5b,c).
To further substantiate our hypothesis that T-oligo treatment
mimics physiological exposure of the 3' telomere overhang fol-
lowing telomere loop disruption [9-11,13,15,17], we intro-
duced TRF2DN [20] into MCF-7 cells, a manipulation known to
disrupt the telomere loop and to lead to exposure and diges-
tion of the 3' overhang [15,17,20]. AdTRF2DN, but not a con-
trol AdGFP vector, induced γ-H2AX and p53 in MCF-7 cells
over the same time course as T-oligo (Figure 5d), supporting
our hypothesis.
T-oligo effect on MCF-7 cells is comparable to that of 
cisplatin and ICI 182,780
To compare the T-oligo effect to that of a recognized anti-
breast cancer chemotherapeutic agent, cisplatin [44-48], and
to an anti-estrogen frequently used to treat estrogen receptor
positive breast cancers [49-51], MCF-7 cells were treated
with customary doses of cisplatin (10 μM), the anti-estrogen
ICI 182,780 (100 nM) or T-oligo (40 μM) as above (Figure 6).
Within 5 days after a single treatment, compared to diluent,
cisplatin decreased MCF-7 yield by 82 ± 0.1% and T-oligo did
so by 79 ± 0.02%, an insignificant difference (p = 1.0; Figure
6a). Similarly, compared to diluent, within 5 days after a single
treatment with ICI 182,780 or T-oligo, cell yield decreased by
72 ± 0.1% and 84 ± 0.02%, respectively (Figure 6b). Interest-
ingly, in this comparison, T-oligo was significantly more effec-
tive than the anti-estrogen ICI 182,780 (p < 0.005).
T-oligo affects adriamycin-resistant breast cancer cells
Multidrug resistance develops in cancer cells as a result of
overexpression of a P-glycoprotein MDR-1 that acts as an
efflux pump for various anticancer drugs and also inhibits
Figure 5
T-oligo and telomeric repeat binding factor dominant negative construct (TRF2DN) activate cell cycle- and apoptosis-regulatory proteins in breast  cancer cells T-oligo and telomeric repeat binding factor dominant negative construct (TRF2DN) activate cell cycle- and apoptosis-regulatory proteins in breast 
cancer cells. (a) Compared with control oligo (C) and diluent (D) alone, T-oligo (T) substantially induced the phosphorylation of p53 (Ser15), p95/
Nbs1 (Ser343) and H2AX (Ser139) and the level of E2F1. In MCF-7 cells, T-oligo also induced the phosphorylation of ataxia telangiectasia mutated 
(ATM; Ser1981) and the levels of p53 and the p53-dependent p21 and BAX proteins. (b) Compared with control oligo (C) and diluent (D), T-oligo 
(T) only slightly induced the phosphorylation of p53 and H2AX in normal mammary epithelial (NME) cells. (c) Graphic representation of band inten-
sity as fold induction above diluent. (d) adenovirus (Ad)TRF2DN, but not the control Ad-green fluorescent protein (GFP) vector, induced the phos-
phorylation of H2AX and p53 in MCF-7 cells. c-myc expression confirms successful transfection of the cells with AdTRF2DN. Actin serves as a 
loading control. One of three representative experiments is shown.Breast Cancer Research    Vol 9 No 1    Yaar et al.
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apoptosis, thus reducing the responsiveness of cancer cells to
chemotherapeutic agents [52]. Thus, agents that are effective
in such non-responsive cells would serve an important role as
a second generation anti-cancer treatment option.
To determine if T-oligo is effective in MDR-1-positive cells,
adriamycin-resistant MCF-7 cells (Adr/MCF-7), known to
express high MDR-1 levels [53], were used after confirmation
of persistent high expression of the P-glycoprotein (data not
shown). Unlike the parental MCF-7, Adr/MCF-7 cells prolifer-
ate in the presence of adriamycin (Figure 7a). Supplementa-
tion with T-oligo on day 0 decreased Adr/MCF-7 cell yields in
both the presence and absence of adriamycin (p < 0.03) by 58
± 14% through at least 96 hours (Figure 7b). Also, compared
to diluent and control oligo, T-oligo increased the percent of
cells in the S phase within 48 hours through 96 hours (p <
0.04; Figure 7c) and induced apoptosis, as determined by the
shift in the fluorescent peak observed in the TUNEL analysis at
96 hours (Figure 7d). T-oligo-induced phosphorylation of p53
and H2AX in Adr/MCF-7 cells was also comparable to that in
parental MCF-7 cells (Figure 7e).
T-oligo increases survival of mice injected intravenously 
with MCF-7 cells
On-going work in our laboratory has established that many T-
oligos exert anti-cancer effects in vitro and/or in vivo, with
molar efficacy determined by several features [18]. To examine
T-oligo effects in vivo, we selected a 16-base T-oligo and first
compared its in vitro efficacy to that of the original 11-base T-
oligo. At lower concentrations (10 μM and 20 μM), the 16-
base T-oligo inhibited MCF-7 yield significantly more than the
11-base T-oligo at 96 hours (64 ± 0.01% versus 31 ± 0.09%,
10 μM, p < 0.001; 74 ± 0.01% versus 45 ± 0.19%, 20 μM, p
< 0.04), although inhibition at 40 μM was comparable (73 ±
0.01% versus 64 ± 0.03%, p = 0.25) (Figure 8a). In addition,
at 20 μM the 16-base T-oligo induced substantially more p53
and H2AX phosphorylation than the 11-base T-oligo within 48
hours (Figure 8b), demonstrating a higher molar efficacy for
the 16-base T-oligo compared to the 11-base T-oligo on MCF-
7 cells in vitro. Doses of roughly equivalent molar efficacy were
selected for comparison in the mouse model.
We then injected MCF-7 cells into the tail vein of SCID mice,
a protocol expected to yield tumors in multiple organs and to
kill the mice [54]. After 3 days and 31 days, when the first
mouse died (a diluent control but still blinded to the investiga-
tors), all remaining mice were treated with diluent alone or
amounts of T-oligo calculated to yield peripheral blood con-
centrations of 40 μM (11mer) or 20 μM (16mer) if instantly
diluted into the animals total blood volume: 120 nmoles or
approximately 23 mg/kg per injection of the 11-base T-oligo or
60 nmoles or 15 mg/kg of the 16-base T-oligo. Injections were
given twice daily for 5 days for a total of 20 injections. As
expected, between 3 and 6 weeks, all controls either died or
had to be sacrificed because of rapid weight loss. Mice
treated with the 11mer had statistically longer survival (p <
0.007), with 1 of 5 remaining healthy through at least 30
weeks, and 75% of mice treated with the 16-base T-oligo sur-
vived without weight loss or other evidence of disease through
30 weeks (p < 0.01, control versus 16-base T-oligo), when the
experiment was terminated (Figure 8c). Autopsies of the
11mer-treated mice that died at 6 to 8 weeks and the 16mer-
treated mice that were sacrificed on the 30th week of the
experiment revealed macroscopic tumor deposits similar to
those in the diluent-treated mice at their time of death, on aver-
age 2 and 28 weeks earlier, respectively. Histological analysis
of several tissues, including bone marrow, liver, jejunum, brain,
lung, kidney and skin, of a SCID mouse injected 24 hours ear-
lier with T-oligo failed to reveal any evidence of T-oligo toxicity.
Discussion
Our data demonstrate remarkable effects of T-oligo on MCF-7
human breast cancer cells in vitro and on xenograft tumor
Figure 6
T-oligo effect on MCF-7 cells is comparable to that of cisplatin and ICI  182,780 T-oligo effect on MCF-7 cells is comparable to that of cisplatin and ICI 
182,780. MCF-7 cells were treated with cisplatin (10 μM), the anti-
estrogen ICI 182,780 (100 nM) or T-oligo (40 μM) once and cell yields 
were determined at different intervals. (a) Within 5 days cisplatin 
decreased MCF-7 yield by 82 ± 0.1% and T-oligo did so by 79 ± 
0.02% compared to diluent. The difference between the T-oligo and 
cisplatin effects was not significant (p = 1.0). (b) Compared to diluent, 
ICI 182,780 or T-oligo caused decreases in cell yield of MCF-7 cells of 
72 ± 0.1% and 84 ± 0.02%, respectively. T-oligo was significantly 
more effective than ICI 182,780 (p < 0.005).Available online http://breast-cancer-research.com/content/9/1/R13
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growth in vivo. In vitro, T-oligo induces growth arrest, followed
by apoptosis or senescence. Interestingly, a single dose of the
hydrolysable T-oligo, with a half-life in serum-containing
medium of approximately four to six hours [55], induces these
responses, possibly attributable to a prolonged half-life of tel-
omere homolog oligonucleotides once in the nucleus [56].
Similarly in vivo, delivering T-oligos intravenously twice daily
for two periods of five days each appears to rescue some mice
from otherwise rapidly fatal innocula of tumor cells and to sig-
nificantly increase survival overall.
We found that T-oligos are taken up by cells and localize to the
nucleus within 30 to 60 minutes after addition to culture
medium. Interestingly, it was not necessary to use special
delivery systems, such as electroporation, and DNA-liposome
and DNA-polymer complexes, used in some studies [57]. This
is consistent with our own previous studies [9,19] and other
investigators who report similar uptake of oligonucleotides in
other cell types without the use of special delivery systems
[58,59]. Although the precise mechanism of oligonucleotide
uptake is unclear, cell surface receptors have been proposed
to perform this function [58,60].
T-oligo rapidly decreased the yields of both breast cancer
MCF-7 cells and NME cells, compared to actively proliferating
controls, likely by inducing an S phase arrest, but appeared to
induce apoptosis and senescence only in MCF-7 cells. This
differential T-oligo effect is not due to selective uptake, as T-
oligo is taken up by normal and malignant cells equally well,
but rather to different cellular responses. In this study we show
significantly less activation of downstream effectors by T-oligo
in normal NME cells compared to MCF-7 malignant cells, and
it is possible that, below a certain phosphorylation threshold
for p53 and H2AX, apoptosis and senescence do not occur.
This result is consistent with differences in response to T-oligo
previously observed between normal human melanocytes and
malignant melanoma cells [13], normal murine B cells and B
cell lymphoma cells [61], and normal human astrocytes and
glioblastoma cells [62].
In MCF-7 breast cancer cells, T-oligos activate and induce
DNA damage response proteins that cause apoptosis and
senescence of cells. Senescence was determined by β-gal
activity and failure to incorporate BrdU or to phosphorylate
pRb after fresh medium supplementation. Although the other-
wise senescent-like MCF-7 cells were arrested in S phase, not
in G0/G1, as observed with fibroblasts serially passaged to
senescence and then refractory to cell division despite provi-
sion of fresh serum-containing medium [63,64], this is identi-
cal to the status of newborn human fibroblasts rendered
senescent by prolonged T-oligo treatment. These cells are
also in S phase arrest after 7 days but, if provided fresh
medium, largely progress over 24 hours to G0/G1, and then
irrevocably arrest [10].
Our model for explaining the T-oligo effect hypothesizes the
existence of innate anti-cancer responses in all cells, normally
triggered by opening of the telomere loop and exposure of the
Figure 7
T-oligo affects adriamycin resistant breast cancer cells T-oligo affects adriamycin resistant breast cancer cells. (a) Unlike MCF-7 cells, Adr/MCF-7 cells proliferate in the presence of adriamycin. (b) Sup-
plementation with T-oligo on day 0 decreased Adr/MCF-7 cell yields in both the presence and absence of adriamycin for at least 96 hours (58% ± 
14%, p < 0.03, n = 4). (b) T-oligo also increased the percent of cells in the S phase within 48 hours and through 96 hours (p < 0.04, n = 2) and (d) 
induced apoptosis as determined by TUNEL analysis at 96 hours. (e) T-oligo induced the phosphorylation of p53 and H2AX comparably to MCF-7 
cells (Figure 5a). C, control-oligo; D, diluent; T, T-oligo.Breast Cancer Research    Vol 9 No 1    Yaar et al.
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single-stranded 3' overhang but also by T-oligos that mimic the
overhang.
Consistent with our hypothesis, the same molecular pathways
leading to apoptosis/senescence are activated by either T-
oligo treatment or telomere loop disruption through ectopic
expression of TRF2DN in either MCF-7 cells in the present
study or in fibroblasts as reported by our group [65] and other
investigators [10,66]. While the muted response to T-oligo of
normal versus malignant cells has important clinical implica-
tions, its basis is not clear. Our model hypothesizes the exist-
ence of innate anti-cancer responses intended to prevent
further proliferation of dysregulated cells, responses normally
triggered by opening of the telomere loop and exposure of the
3' overhang. We further hypothesize that this mechanism is
defeated in malignant cells by over-expression of proteins,
such as telomerase, that bind and obscure the telomere over-
hang [8], but that provision of T-oligos replaces the obscured
TTAGGG sequence and initiates the DNA damage-like signal-
ing. This hypothesis is consistent with the observations that
knock-down of a non-enzymatic component of telomerase
(hTER) in malignant cells may lead to their apoptosis within
five days without telomere shortening [67,68], and with the
recent demonstration that ATM, ATR and their downstream
effector DNA damage response proteins are normally
recruited to the telomeres during S phase as part of a cellular
mechanism that assures genomic integrity [65]. It is unlikely
that expression of telomerase, in the absence of genomic
lesions and dysregulated growth, is sufficient to cause T-oligo
signaling to proceed through induction of apoptosis or senes-
cence, as normal cells known to express telomerase, such as
mitogen-stimulated rapidly proliferating lymphocytes, do not
undergo apoptosis in response to T-oligo treatment, while syn-
geneic lymphoma cells do [61].
Also consistent is the observation that knock-down of POT-1,
a telomere-specific single-stranded DNA binding protein [69],
also elicits apoptosis (in MCF-7 cells) and senescence (in
fibroblasts; not reported in MCF-7 cells) associated with tel-
omere loop disruption and degradation of the 3' overhang
[70]. In this latter case, because POT-1 associates with TRF2
[70] and TRF2 has been shown, at least in vitro, to bind and
inhibit ATM [71], it has been suggested that simple removal of
a direct inhibitory effect of POT-1/TRF2 complexes on ATM
accounts for the observed ATM activation. However, this
mechanism could not account for the apparently identical sig-
naling pathways activation by telomerase knockdown [67,68]
or treatment with T-oligos that does not result in telomere loop
disruption and consequent digestion of the endogenous 3'
overhang [9,15]. Furthermore, over-expression of POT-1 abro-
gates DNA damage responses induced by POT-1 sequestra-
tion with TRF2DN [70]. This finding suggests that masking of
the TTAGGG repeat sequence by binding of excess POT-1
even after opening of the telomere loop is sufficient to block
signaling through ATM and p53, and that exposure of the oth-
erwise concealed TTAGGG repeat sequence after POT-1
knock-down is a more likely causal event. That T-oligos substi-
tute for exposure of the telomere 3' overhang as a stimulus for
DNA damage-like signaling is further suggested by the recent
demonstration that WRN, the protein mutated in Werner syn-
drome [72] and known to localize to the telomere and to
resolve the telomere loop structure [73,74], is required for T-
oligo initiated signaling [15]. Furthermore, T-oligo-induced
Figure 8
T-oligo increases survival of mice injected intravenously with MCF-7  cells T-oligo increases survival of mice injected intravenously with MCF-7 
cells. (a) MCF-7 cells received fresh serum-containing medium supple-
mented with increasing concentrations (10 to 40 μM) of the 11mer or 
16mer T-oligos or diluent alone and were harvested at 96 hours. At 10 
μM and 20 μM, the 16mer inhibited MCF-7 yield substantially more 
than the 11mer, and 20 μM 16mer reduced cell yields comparably to 
40 μM 11mer. (b) MCF-7 cells were supplemented with 11mer or 
16mer T-oligos (20 μM) or diluent (Dil) alone. Within 48 hours both T-
oligos induced H2AX and p53 phosphorylation, but this occurred to a 
greater extent with the 16-base T-oligo. (c) SCID mice inoculated intra-
venously with MCF-7 cells received intravenous T-oligo or diluent injec-
tions as per the Materials and methods. Doses giving comparable 
growth inhibition at 96 hours were used: 20 μM 16mer versus 40 μM 
11mer, equivalent to 60 versus 120 nmoles injected into the estimated 
murine 1.5 ml peripheral blood volume. Both T-oligos increased survival 
of the mice, with the 16mer having a greater effect.Available online http://breast-cancer-research.com/content/9/1/R13
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γH2AX foci, also characteristic of senescent cells [41], form at
or immediately adjacent to telomeres [15].
Drug resistance is the major reason for treatment failure in
most human cancers [75-78]. While few cancers eventually
display an inherent resistance to chemotherapy, the majority of
cancers acquire multi-drug resistance as a result of over-
expression of the P-glycoprotein encoded by the MDR-1 gene
that pumps out of the cell several structurally unrelated
chemotherapeutic drugs as well as other compounds [79].
Furthermore, in some cancer cells, in addition to its efflux
pump action, P-glycoprotein has an anti-apoptotic effect
[80,81]. Thus, identifying treatment options for MDR-1
expressing cancers is of utmost importance. Our experiments
show that MCF-7 cells resistant to adriamycin (Adr/MCF-7)
are sensitive to T-oligo. The same regulatory proteins are acti-
vated in MCF-7 cells resistant or not resistant to adriamycin,
leading to their apoptosis. Thus, T-oligos constitute a novel
class of anti-cancer agents that alone or in combination with
conventional drugs may improve treatment responses for
breast carcinoma and other cancers.
In the current study we compared the efficacy of an 11 base
and a 16 base oligonucleotide with 100% and 81% telomere
homology, respectively. Surprisingly, the 16 base T-oligo was
more effective on an equimolar basis at inducing H2AX and
p53 phosphorylation and decreasing cell yields in vitro, and
half the dose in nanomoles, it was more effective than the
11mer at enhancing survival of MCF-7-injected mice. Of note,
T-oligos require 3'→5' nucleolytic digestion to be active, pre-
sumably by the WRN exonuclease and helicase that is
required for T-oligo-induced signaling [15]. It is possible that
longer T-oligos provide a better substrate for WRN, but addi-
tional experiments are required to delineate this point and to
optimize the T-oligo as a cancer chemotherapeutic agent.
Nevertheless, both T-oligos demonstrated anti-tumor effects
as determined by mice survival when injected intravenously
into SCID mice previously injected with MCF-7 cells. T-oligos
were given twice a day for only two periods of 5 days, 3 days
after MCF-7 inoculation and 31 days after their inoculation, at
the time control mice began to die or had to be sacrificed.
Although the dosing regimen was arbitrary, it was sufficient to
allow survival of 75% of the 16mer-treated animals for 23
weeks after the last treatment and for 30 weeks after inocula-
tion with MCF-7 cells before the experiment was terminated.
In contrast, diluent-treated mice did not survive beyond six
weeks. The less effective 11mer also increased the survival of
the tumor-bearing mice.
Our experiments show that T-oligos are effective against p16-
null MCF-7 breast cancer cells as well as adriamycin-resistant
P-glycoprotein-expressing cells that additionally have non-
functional p53, suggesting that T-oligos may be effective
against at least some chemotherapy-resistant tumors.
Importantly, T-oligos are effective in a SCID mouse model of
metastatic human breast cancer.
Conclusion
We suggest that T-oligos provide a novel approach to treating
human malignancies, including breast cancer. Our data further
support the existence of an innate anti-cancer mechanism that
is disabled in cancer cells but that can be triggered by
telomere homolog oligonucleotides delivered to the nucleus in
the form of T-oligos.
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